- Home
- XPON vs PHIO Comparison
XPON vs PHIO Comparison
Compare XPON & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | PHIO |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 12.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | XPON | PHIO |
|---|---|---|
| Price | $0.90 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 338.3K | ★ 362.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,417,947.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $0.97 |
| 52 Week High | $5.50 | $9.79 |
Technical Indicators
Market Signals| Indicator | XPON | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 31.72 |
| Support Level | $0.82 | $1.04 |
| Resistance Level | $1.26 | $1.20 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.39 | 10.35 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.